Angiogenesis involves a complex set of cell-cell and cellextracellular matrix (ECM) interactions that coordinately promote and inhibit blood vessel growth and sprouting. Although many factors that promote angiogenesis have been characterized, the identities and mechanisms of action of endogenous inhibitors of angiogenesis remain unclear. Furthermore, little is known about how cancer cells selectively circumvent the actions of these inhibitors to promote pathological angiogenesis, a requisite event for tumor progression. Using mosaic mouse models of the malignant brain cancer, astrocytoma, we report that tumor cells induce pathological angiogenesis by suppressing expression of the ECM protein receptor avb8 integrin. Diminished integrin expression in astrocytoma cells leads to reduced activation of latent TGFbs, resulting in impaired TGFb receptor signaling in tumor-associated endothelial cells. These data reveal that astrocytoma cells manipulate their angiogenic balance by selectively suppressing avb8 integrin expression and function. Finally, these results show that an adhesion and signaling axis normally involved in developmental brain angiogenesis is pathologically exploited in adult brain tumors.
Introduction
The mammalian brain is a highly vascularized organ, with neural cells and blood vessels communicating through direct cell-cell contacts as well as secreted growth factors and cell-extracellular matrix (ECM) proteins (Bautch and James, 2009; McCarty, 2009a) . Integrins are cell-surface receptors for many ECM ligands (Desgrosellier and Cheresh, 2010) , and integrin-mediated adhesion and signaling events are vital in vascular development and homeostasis in the brain (McCarty, 2009b) . In particular, the neuroepithelial cell-expressed integrin, avb8, is essential for normal blood vessel growth and sprouting during brain development (McCarty et al., 2002; Zhu et al., 2002) . Selective ablation of av or b8 integrin gene expression in embryonic mouse neural progenitors causes brain-specific vascular phenotypes, including endothelial cell hyperplasia, the formation of blood vessels with glomeruloidlike tufts and intracerebral hemorrhage (McCarty et al., 2004; Proctor et al., 2005) . avb8 integrin is a receptor for latent forms of TGFb1 and TGFb3 and mediates their bioactivation (Cambier et al., 2005) . Perturbation of integrin-mediated activation of latent TGFb1 and TGFb3 leads to brain-specific vascular defects that phenocopy the pathologies in integrin knockouts (Mu et al., 2008) . Hence, avb8 integrin-mediated TGFb activation and signaling controls normal embryonic blood vessel morphogenesis and blood-brain barrier development.
In the post-natal brain avb8 integrin is expressed in neural stem and progenitor cells (Mobley et al., 2009) , which are likely cells of origin for the malignant brain cancer astrocytoma (Zheng et al., 2008; Alcantara Llaguno et al., 2009) . High-grade astrocytomas, particularly glioblastoma multiforme (GBM), are defined in part by the development of hallmark angiogenesis pathologies, including vascular cell hyperproliferation and hemorrhage owing to breakdown of the intratumoral blood-brain barrier (Kaur et al., 2004; Jain et al., 2007) . As detailed above, these tumor-induced vascular pathologies are strikingly similar to phenotypes that develop in mice that are genetically deficient for avb8 integrinmediated activation of TGFb1 and TGFb3. Whether astrocytoma cells manipulate integrin-mediated TGFb activation and signaling pathways to induce pathological angiogenesis, however, remains uncertain. Here, we report that diminished avb8 integrin expression and function in astrocytoma cells has a central role in promoting pathological angiogenesis and abnormal vascular permeability. These results are the first to link deregulation of avb8 integrin function to vascular pathologies that are defining features of high-grade astrocytomas.
Results

Analysis of avb8 integrin protein expression in human astrocytoma cell lines
On the basis of the brain-specific angiogenesis phenotypes that develop in av and b8 integrin knockout mice, we hypothesized that abnormal avb8 integrin expression or function may also contribute to angiogenesis pathologies in malignant brain tumors. Therefore, lysates from five established human astrocytoma cell lines were immunoblotted to determine expression levels of av and b8 integrin proteins. As shown in Figure 1a , differing levels of b8 integrin protein expression were detected in the various human cell lines. U87 and LN18 cells expressed low levels of b8 integrin, whereas LN229, U251 and SNB19 astrocytoma cells expressed robust levels of b8 integrin protein. av integrin protein levels were constant in the different astrocytoma cell lines, likely owing to expression of other integrin b subunits, for example, b3 and b5, that heterodimerize with av integrin (Skuli et al., 2009) . To establish in vivo links between b8 integrin protein levels and tumorinduced angiogenesis, we stereotactically implanted U87 or SNB19 cells into the brains of immunocompromised mice. All mice injected with U87 cells (n ¼ 5, 5 Â 10 5 cells per mouse) developed neurological deficits within 6 weeks after injection. Macroscopic analyses of perfused brains revealed large, wellvascularized and hemorrhagic primary tumors that filled most of the injected hemisphere (Supplementary Figure 1A ). Immunohistochemical analyses using an antibody directed against the endothelial cell-expressed protein CD34 revealed blood vessels with distended and sinusoidal-like morphologies in U87 tumors (Figure 1c ). Mice implanted with SNB19 cells (n ¼ 3, 5 Â 10 5 cells injected per mouse) also developed neurological phenotypes within 6 weeks; however, intracranial SNB19 tumors were not macroscopically apparent (Supplementary Figure 1B) . Microscopic analysis of hematoxylin and eosin (H&E)-stained brain sections from SNB19 tumor-bearing mice revealed focal and invasive lesions, often in periventricular regions of the brain (Figure 1d ). Anti-CD34 immunohistochemistry ( Figure 1e ) revealed that microvessels within SNB19 tumors were relatively uniform in diameter, nonhemorrhagic and morphologically distinct from vessels in U87 tumors ( Figure 1c ).
Isolation of primary astroglial progenitor cells from wild-type and b8À/À mice Although the analyses of the human astrocytoma cell lines and resulting xenograft tumors suggest connections between b8 integrin expression and intratumoral vascular pathologies (Figure 1 ), there are many limitations associated with studying glioma cell lines. For example, these cell lines have been sequentially passaged over several years, harbor different genetic alterations and do not express markers commonly expressed in astrocytomas in situ (Ishii et al., 1999) . Therefore, we decided to analyze functions for b8 integrin in tumorinduced angiogenesis using a more genetically tractable model of astrocytoma.
Astroglial cells, which are putative cells of origin for astrocytomas, were cultured from cerebral cortices of post-natal wild-type ( þ / þ ) or b8 integrin homozygous (b8À/À) mutant mice. Newborn b8À/À mice were easily distinguished from control littermates by macroscopically apparent intracerebral hemorrhage (Figures 2a and c); however, all genotypes were confirmed by PCR-based methods using genomic DNA isolated from tail snips as previously described (Zhu et al., 2002) . As shown in Figures 2b and d , nearly all wild-type Figure 1 b8 integrin protein is differentially expressed in human astrocytoma cell lines. (a) Detergent-soluble lysates prepared from five human astrocytoma cell lines were immunoblotted with antibodies recognizing av and b8 integrin proteins. Note that U87 and LN18 cells express low levels of b8 integrin protein, whereas LN229, SNB19 and U251 cell express robust levels of b8 integrin protein.
(b, c) U87 glioma cells were stereotactically implanted into the striatum of immunocompromised mice (n ¼ 5) and coronal tumor sections were analyzed by H&E staining (b) or anti-CD34 immunohistochemistry (c). Note that U87 cells form large intracranial tumors that are well vascularized and contain hemorrhagic and sinusoidal-like vessels (arrows in c). Boxed areas in (b) ( Â 100) are shown at higher magnification ( Â 400) in panel (c). (d, e) SNB19 glioma cells were stereotactically implanted into the striatum of immunocompromised mice (n ¼ 3) and coronal tumor sections were analyzed by H&E staining (d) or anti-CD34 immunohistochemistry (e). SNB19 tumors formed in periventricular regions of the brain. These focal lesions contain blood vessels (arrows in e) that are morphologically distinct from blood vessels in U87 tumors (arrows in c). Boxed areas in d ( Â 100) are shown at higher magnification ( Â 400) in panel (e). and b8À/À primary cells were immunoreactive for Nestin, a marker for neural progenitor cells in the brain (Stipursky and Gomes, 2007) . Most cells also expressed glial fibrillary acidic protein (GFAP), a marker for differentiated astrocytes and some neural stem cells (Mori et al., 2005) . On the basis of co-expression of Nestin and GFAP in the majority of cells, we refer to these cells throughout this report as 'astroglial progenitors'. To analyze avb8 integrin protein expression in primary astroglial progenitors, we surface-labeled the cells with an amine-reactive derivative of biotin. Anti-integrin antibodies were then used to immunoprecipitate integrin proteins from detergent-soluble lysates. Primary wild-type astroglial progenitors expressed avb5 and avb8 integrins (Figure 2e ), which is consistent with previous reports for av integrin expression in primary human astrocytes (Cambier et al., 2005) . b8À/À astroglial progenitors expressed avb5 integrin protein at levels similar to wild-type cells, but did not express the avb8 integrin heterodimer, due to b8 integrin gene ablation (Figure 2e ). avb1, avb3 and avb6 integrins were not detected in primary astroglial progenitor cells isolated from wild-type and knockout mice (data not shown). Lastly, primary wild-type and b8À/À cells did not show obvious differences in proliferation under adherent growth conditions (Figure 2f ).
Oncogene-mediated transformation of primary astroglial progenitor cells leads to diminished avb8 integrin expression Astroglial progenitors were immortalized and transformed using retroviral-delivered oncogenes that target growth pathways commonly altered during astrocytoma initiation and progression. Cells were first immortalized with a retrovirus expressing the human papilloma virus E6 and E7 proteins (Sonoda et al., 2001b) , which inhibit the expression and function of the p53 and Rb tumor suppressors, respectively. The p53 gene is commonly mutated or deleted in human gliomas (Furnari et al., 2007) ; furthermore, both Rb and p53 negatively regulate the functions of the Ink4a/Arf tumor suppressors, which are commonly deleted in malignant astrocytomas (Bachoo et al., 2002; Uhrbom et al., 2002) . Pooled Figure 2 Mouse astroglial progenitor cells, a presumptive cell type of origin for astrocytomas, express robust levels of endogenous avb8 integrin. (a, c) Images of whole brains dissected from wild-type (a) and b8À/À (c) newborn littermates. Note the hemorrhage throughout the b8 integrin knockout brain. (b, d) Primary astroglial progenitor cells were cultured from cerebral cortices of wild-type (b) or b8À/À (d) neonatal mice and immunofluorescently stained with antibodies recognizing GFAP (upper panels) and nestin (middle panels). Note that many cells co-express GFAP and Nestin protein (lower panels in b, d). (e) Analysis of integrin protein expression in primary astroglial progenitors. Wild-type and b8À/À astroglial progenitor cells were incubated with amine-reactive biotin to label cell-surface proteins. Lysates were immunoprecipitated with antibodies directed against av, b5 or b8 integrins. Note the absence of avb8 integrin expression in b8À/À cells. (f) Primary b8À/À astroglial progenitor cells do not show obvious growth differences in vitro, compared with wild-type controls. Cell proliferation under adherent conditions was quantified by counting viable cells every 24 h over a period of 4 days (n ¼ 3 per genotype per time point). Error bars represent standard deviations. populations of immortalized cells were then transformed using a retrovirus expressing oncogenic H-Ras ( G12V H-Ras) (Sonoda et al., 2001b) . Ras activities are often hyperactivated in astrocytomas, due to gene mutations or elevated expression of upstream receptor tyrosine kinases (Holland et al., 2000) . Two independent preparations of wild-type and b8À/À transformed cells were generated using primary cells isolated from different neonatal mice. All in vitro and in vivo results presented below represent one of the two preparations; however, parallel experiments with the second preparation of transformed cells generated similar outcomes (data not shown).
Immunoblot analyses confirmed similar levels of Ras and E7 protein overexpression in transformed cells ( Figure 3a ). We also detected increased expression of CD133/Prominin-1, a transmembrane protein that marks some embryonic neural stem cells (Uchida et al., 2000) and tumor-initiating cells in GBM and other solid malignancies (Singh et al., 2004; Bao et al., 2006a; O'Brien et al., 2007) following cell transformation ( Figure 3b ). There was a complete loss of expression of GFAP following cell transformation; in contrast, Nestin protein levels remained unchanged ( Figure 3b ). This upregulation of CD133/Prominin-1 and downregulation of GFAP expression suggest oncogene-induced cell 'dedifferentiation', similar to what others have proposed for transformed astroglia (Bachoo et al., 2002; Uhrbom et al., 2002) . Lastly, genetic ablation of b8 integrin did not alter adherent growth properties of transformed astroglial progenitor cells (Figure 3c ), and wild-type and b8À/À transformed cells also generated similar numbers of colonies in threedimensional soft agar growth assays (Figure 3d ).
Transformed wild-type cells showed significantly reduced levels of av and b8 integrin proteins, although the levels of b1 integrin protein were not altered in wild-type or b8À/À transformed cells ( Figure 4a ). Integrin protein expression was quantified in primary versus transformed cells using an anti-av antibody. As shown in Figure 4b , approximately 90% of wildtype and b8À/À primary cells expressed detectable levels of cell-surface av integrin protein. In contrast, oncogene-mediated transformation resulted in an approximately 50% reduction in av integrin protein expression ( Figure 4b ). Since b8 integrin heterodimerizes exclusively with the av subunit (Milner et al., 2001) , the reduction in b8 protein levels in wild-type transformed cells is likely due to reduced levels of av integrin protein; indeed, av protein levels are reduced in oncogene-transformed b8À/À cells ( Figure 4b ). We detected reduced levels of b5 integrin, which also heterodimerizes exclusively with av integrin, in wild-type and b8À/À transformed astroglial cells (data not shown). Levels of avb8 integrin protein expression progressively decreased following sequential passaging of wild-type transformed astroglial cells ( Figure 4c ). The diminished avb8 integrin protein expression in highly passaged transformed cells was not a secondary consequence of long-term growth in vitro, as we did not detect diminished integrin expression in sequentially passaged primary mouse neurospheres isolated from the post-natal subventricular zone (Supplementary Figure 2) .
Analysis of b8 integrin-dependent tumor angiogenesis and vascular permeability
The ability of transformed astroglial progenitors to form astrocytoma-like tumors in vivo was analyzed by stereotactically implanting wild-type and b8À/À cells into the striatum of immunocompromised mice. Owing to the loss of avb8 integrin expression in Figure 3 Oncogene-induced transformation of primary astroglial progenitor cells. (a) Detergent-soluble lysates from wild-type and b8À/À primary and transformed cells were immunoblotted with antibodies directed against Ras and E7 proteins. (b) Lysates prepared from primary and transformed astroglial progenitor cells were immunoblotted with anti-Nestin, anti-CD133/Prominin-1, anti-GFAP and anti-actin antibodies. Note the increase in CD133 expression and decrease in GFAP expression in transformed cells. Lysates used for these immunoblots are the same as those analyzed in Figure 4a , therefore the actin immunoblots are the same. (c) Proliferation indices for adherent wild-type and b8À/À transformed astroglial progenitors were determined by counting the total numbers of cells every 24 h over 4 consecutive days (n ¼ 3 samples per genotype per time point). (d) Adhesion-independent cell growth in soft agar was quantified by counting crystal violet-stained colonies (n ¼ 3 samples per genotype). The differences in colony numbers formed from wild-type and b8À/À cells were not statistically significant. All error bars represent standard deviations.
high-passage cells (Figure 4c ), all studies were performed with cells cultured for less than four passages following oncogene transformation. All mice injected with either wild-type or b8À/À transformed astroglial progenitors developed neurological phenotypes and died within 45 days after injection. Microscopic examination of brains injected with wild-type and b8À/À transformed cells (n ¼ 20 mice per genotype) revealed tumor formation in 100% of experimental animals.
In comparison to wild-type tumors, there were striking differences in the macroscopic appearance of tumors generated from transformed b8À/À astroglial progenitors (Figures 5a and b) . Similar results were observed following the injection of transformed avÀ/À astroglial cells (data not shown). Most b8À/À tumors (17 of 20 analyzed) showed grossly obvious intratumoral hemorrhage; in contrast, only two of 20 wild-type astrocytomas showed grossly obvious hemorrhage. Kaplan-Meier survival plots revealed that mice with b8À/À tumors (n ¼ 16) died significantly earlier than mice harboring wild-type tumors (n ¼ 20). As shown in Figure 5c , 50% of mice with b8À/À tumors were alive at 26 days after implantation, whereas mice harboring wild-type tumors showed 50% survival at 33 days. The most probable reason for the accelerated death of mice bearing b8À/À astrocytomas relates to the severe intratumoral hemorrhage in these animals. We have noticed that extravasated red blood cells accumulate in the brain ventricles and likely obstruct the flow of cerebrospinal fluid, leading to hydrocephalus and neurological deficits. In a separate cohort of mice, we compared tumor volumes at 14 and 21 days after intracranial injection of wild-type and b8À/À transformed cells (n ¼ 9 mice per genotype per time point). Tumor volumes were quantified in H&E-stained brain sections by measuring tumor diameter at the largest cross-sectional area; however, no obvious differences were detected in sizes of tumors derived from wild-type and b8À/À transformed cells at 14 and 21 days after implantation ( Figure 5d ).
Microscopic analysis of H&E-stained tumor sections revealed that wild-type tumors (Figure 6a ) were highly vascularized and showed pathological features similar to grade III anaplastic astrocytoma, consistent with previous reports (Sonoda et al., 2001a (Sonoda et al., , 2003 . H&E-stained sections from b8À/À tumors, however, revealed hemorrhagic blood vessels with tortuous and distended morphologies (Figure 6b ). Both wild-type and b8À/À intratumoral blood vessels were lined with CD34expressing vascular endothelial cells (Figures 6c and  d) ; however, immunofluorescence-based quantitation revealed significantly more CD34-expressing vessels within b8À/À tumors (Figure 6g ). The severe vascular pathologies within b8À/À tumors made them more similar to grade IV GBM, although other defining features of human GBM, such as regions of pseudopallisading necrosis were not evident in b8À/À tumors (data not shown).
Pericytes are vascular mural cells that closely juxtapose endothelial cells and are necessary for normal blood vessel structure and function (Adams and Alitalo, 2007) . Therefore, we analyzed whether microvascular pericytes were present in wild-type and b8À/À astrocytomas. Most CD34-expressing endothelial cells in wild-type astrocytomas were associated with Desmin þ pericytes (Figure 6e ). b8À/À tumors showed increased numbers of CD34-expressing blood vessels with distended and tortuous morphologies; however, vessels within b8À/À tumors were also associated with Desminexpressing pericytes (Figure 6f ).
Wild-type or b8À/À tumor cells did not express detectable levels of GFAP in vivo, although nonmalignant reactive astrocytes that formed a glial scar around the tumor margins showed robust GFAP expression ( Supplementary Figure 3C) . Wild-type and b8À/À cells maintained Nestin expression and showed patterns of perivascular invasiveness ( Supplementary  Figures 3A and B) .
Rescue of vascular pathologies by forced expression of b8 integrin protein in b8À/À cells To determine whether the vascular pathologies in b8À/À tumors were the direct result of loss of b8 integrin protein, or were due to integrin-independent effects on cell transformation, we restored b8 integrin protein expression in b8À/À cells using a plasmid expressing human b8 integrin protein tagged at the C terminus with the V5 epitope. Protein expression was confirmed by immunoblotting with anti-b8 and anti-V5 antibodies (Figure 7a ).
b8À/À cells stably transfected with empty pcDNA4 plasmid were stereotactically injected into the striatum of immunocompromised mice (n ¼ 5). Resulting intracranial tumors were hemorrhagic and contained dilated blood vessels (Figures 7b, d and f) . In contrast, injection of b8À/À cells forcibly expressing b8V5 integrin protein (n ¼ 5 mice) generated tumors with blood vessels that were fairly uniform in size and non-hemorrhagic ( Figures  7b, c and e ). These data show that the severe vascular pathologies in b8À/À tumors are caused by loss of b8 integrin expression and function, and that these vascular defects can be largely reversed following exogenous expression of b8 integrin protein.
Analysis of integrin-dependent VEGF expression
Prior reports showed that vascular endothelial growth factor (VEGF) is involved in pathological angiogenesis and hemorrhage within brain tumors (Cheng et al., Figure 5 Severe vascular pathologies and diminished survival in mice harboring b8À/À astrocytomas. (a, b) Mice harboring wild-type (a) or b8À/À (b) astrocytomas were cardiac-perfused with fixative and then coronally sliced at 1 mm intervals. Shown are representative brain slices from tumor-bearing mice. Note the obvious hemorrhage in b8À/À tumors (arrows, top right panel). (c) Kaplan-Meier survival plot for mice harboring wild-type (n ¼ 20) or b8À/À (n ¼ 16) astrocytomas, *Po0.001 at 50% survival. (d) A separate cohort of mice harboring wild-type and b8À/À astrocytomas were killed at 14 days (n ¼ 9 per genotype) and 21 days (n ¼ 8 per genotype) after injection. Tumor volumes were quantified in H&E-stained coronal sections by measuring tumor diameters at the largest cross-sectional area; P ¼ 0.529 at 14 days (b8À/À samples in comparison to wild-type samples); P ¼ 0.643 at 21 days (b8À/À samples in comparison to wild-type samples). Error bars represent standard deviations. 1996 Benjamin and Keshet, 1997; Kanamori et al., 2004) . Therefore, levels of VEGF mRNA and protein expression were analyzed in transformed astroglial progenitors and tumors. As shown in Supplementary Figure 4A , we detected decreased expression of the VEGF120 and VEGF164 mRNAs in b8À/À cells. Analysis of VEGF protein expression by enzyme-linked immunosorbent assay also revealed approximately 50% less VEGF in conditioned media from b8À/À cells (Supplementary Figure 4B ), further indicating that b8 integrin positively regulates VEGF gene expression. VEGF protein expression was also analyzed by immunoblotting detergent-soluble lysates prepared from wild-type and b8À/À astrocytomas (n ¼ 2 tumors per genotype). However, we did not detect differences (Supplementary Figure 4C) , likely due to VEGF expression by nonmalignant stromal cells. Along these lines, immunofluorescence staining of wild-type and b8À/À tumors with an anti-VEGF antibody revealed no obvious differences in VEGF protein expression ( Supplementary  Figures 4D and 4E) .
Analysis of integrin-dependent TGFb activation and signaling
We next analyzed integrin-dependent TGFb expression, activation and signaling in transformed astroglial cells and astrocytomas. Integrin-dependent differences in expression of TGFb1, TGFb2 and TGFb3 mRNAs in transformed cells were not obvious as assessed by semi-quantitative RT-PCR (data not shown). b8 integrinmediated activation of latent TGFb1 was measured in vitro using luciferase reporter assays. Wild-type or b8À/À transformed astrocytes were exposed to 10 ng/ml latent TGFb1 for 12 h, and conditioned media were then added to mink lung epithelial cells stably transfected with a reporter plasmid containing a truncated plasminogen activator inhibitor-1 (PAI-1) promoter promoting expression of firefly luciferase (PAI-1 luciferase) (Abe et al., 1994) . As shown in Figure 8a (black bars), in comparison to conditioned media from wild-type cells, there was a significant reduction (approximately 30%) in luciferase activity using conditioned media from b8À/À cells. These data reveal that avb8 integrin in astrocytoma cells promotes the activation of latent TGFb1. However, in the absence of exogenous LAP-TGFb1, a statistically significant increase in luciferase activity was not detected using conditioned media from wild-type and b8À/À transformed cells (gray bars in Figure 8a ), suggesting integrin-independent mechanisms of latent TGFb activation.
We reasoned that the three-dimensional context of the brain tumor microenvironment might reveal more dramatic differences in integrin-dependent TGFb activation/signaling in vascular endothelial cells. Therefore, we analyzed TGFb signaling events in situ using an antibody directed against phosphorylated Smad3 (pSmad3), a canonical TGFb signaling protein that translocates into the nucleus following TGFb receptormediated phosphorylation (Massague, 2008) . As shown in Figure 8b , CD31 þ blood vessels within b8 integrinexpressing astrocytomas showed robust levels of nuclear pSmad3 protein. In contrast, many CD31 þ Figure 6 Histological analyses of wild-type and b8À/À astrocytomas. (a, b) Coronal sections from wild-type (a) or b8À/À (b) astrocytomas stained with hematoxylin and eosin (H&E) and analyzed microscopically ( Â 200). Note the abnormally dilated intratumoral blood vessels in b8À/À astrocytomas (arrows). (c, d) Coronal sections from wild-type (c) and b8À/À (d) astrocytomas were immunostained with an anti-CD34 antibody and visualized ( Â 400) to label vascular endothelial cells (arrows). (e, f) Coronal sections from wild-type (e) and b8À/À (f) astrocytomas were immunofluorescently labeled with anti-CD34 to reveal vascular endothelial cells (green) and anti-desmin to reveal vascular pericytes (red). Note that desmin-expressing pericytes are associated with blood vessels within wild-type and b8À/À astrocytomas. The boxed areas are shown in higher magnification in the lower right corners of each panel. Magnification for panels (e, f), Â 200. (g) Quantitation of CD34 expression in astrocytoma sections. Sections were immunofluorescently labeled with anti-CD34, and four randomly selected fields were analyzed from wild-type and b8À/À tumors (n ¼ 5 mice per tumor genotype). In comparison to wild-type tumors there is significantly more CD34 immunofluorescence in b8À/À astrocytomas, *Po0.001 for b8À/À samples compared with wild-type controls. Error bars represent standard deviations. blood vessels within b8À/À tumors expressed low or undetectable levels of nuclear pSmad3 (Figure 8c ). To more quantitatively assess integrin-mediated TGFb signaling, we sorted vascular endothelial cells from tumors using magnetic beads coated with anti-CD31 antibodies. Freshly prepared cell lysates were then immunoblotted with antibodies directed against phosphorylated forms of Smad2 and Smad3. As shown in Figures 8d, a reduction in phosphorylation of Smad2/3 was apparent in CD31-expressing cells sorted from b8À/À tumors. Laser scanning densitometry was used to quantify the band intensities, revealing that vascular endothelial cells isolated from b8À/À tumors expressed two-fold less total Smad2/3 protein levels. These data suggest that avb8 integrin regulates Smad2/3 protein stability in endothelial cells. The phospho-Smad2/3 band intensities were then normalized to the total Smad2/3 levels; however, we still detected two-fold less pSmad2 and three-fold less pSmad3 in CD31 lysates from b8À/À tumors. These data reveal that the vascular pathologies in astrocytomas correlate with impaired integrin-mediated TGFb activation and signaling through Smad2 and Smad3 in intratumoral endothelial cells. Figure 7 Exogenous expression of b8 integrin rescues astrocytoma-induced angiogenesis pathologies. (a) b8À/À transformed astrocytes were stably transfected with empty vector or a vector expressing human b8 integrin protein tagged at the C terminus with a V5 epitope (b8-V5). Cell lysates were then immunoblotted with an antibody directed against b8 integrin (top panel), V5 (middle panel) or actin (bottom panel). (b) Mice injected with b8À/À transformed astrocytes stably transfected with empty vector (right panel) or b8À/À cells stably expressing b8-V5 protein (left panel) were cardiac-perfused with fixative and brains were coronally sliced at 1 mm intervals. Note the hemorrhage in b8À/À (empty vector) tumors that is absent in the tumors expressing b8-V5 protein (arrows). (c, d) Coronal sections from b8À/À ( þ b8V5) astrocytomas (c) or b8À/À ( þ vector) astrocytomas (d) were stained with hematoxylin and eosin (H&E). Note that the dilated intratumoral blood vessels in b8À/À tumors are diminished in tumors expressing b8-V5 integrin protein (arrows). (e, f) Coronal sections from astrocytomas were immunofluorescently labeled with anti-CD34 to reveal vascular endothelial cells. Note the obvious differences in blood vessel characteristics in the b8À/À þ b8-V5 tumors (e) versus b8À/À tumors (f). Sections in panels (c-e) were analyzed at Â 200 magnification.
Discussion
A major conclusion from this study is that avb8 integrin, an ECM protein receptor that we have previously shown to be essential for embryonic brain angiogenesis, also plays a key role in regulating pathological angiogenesis in astrocytomas growing in the adult brain. Our data reveal the following specific findings: (1) avb8 integrin is differentially expressed in human astrocytoma cell lines, with low levels of integrin expression correlating with increased intratumoral angiogenesis and hemorrhage (Figure 1); (2) primary mouse astroglial progenitor cells, which are presumptive cells of origin for astrocytomas, express robust levels of Figure 8 Impaired TGFb activation and signaling in b8À/À astrocytomas. (a) Diminished TGFb activation in b8À/À cells using a PAI-1-luciferase reporter assay. Conditioned media ( þ /À exogenous LAP-TGFb1) from wild-type (n ¼ 3) or b8À/À (n ¼ 3) transformed astroglial progenitors were transferred to MLECs stably transfected with PAI-1-luciferase followed by analysis of luciferase activity. Conditioned media from wild-type cells pre-treated with LAP-TGFb1 induced robust luciferase activity; however, note the reduced luciferase activity using conditioned media from b8À/À cells, *Po0.0001 compared to conditioned media without LAP-TGFb1; **Po0.004 compared with wild-type cells; ***P ¼ 0.04 compared with wild-type cells. Error bars represent standard deviations. (b, c) Fluorescent images ( Â 400) of coronal sections from b8À/À astrocytomas stably expressing b8-V5 integrin protein (b) or b8À/ astrocytomas transfected with empty vector (c). Sections were immunofluorescently labeled with anti-CD31 (red) to visualize vascular endothelial cells and anti-pSmad3 (green) to monitor canonical TGFb signaling. Note that most vessels within b8 integrinexpressing tumors contain nuclear pSmad3 (arrows in b), whereas vessels within b8À/À tumors are largely negative for nuclear pSmad3 (arrows in c) although some nuclear pSmad3 is detected (arrowhead in c). Boxed areas in (b, c) are shown at higher magnification in lower right corners. (d) Mice injected intracranially with b8À/À ( þ vector) cells or b8À/À ( þ b8V5) cells were killed, tumors were microdissected and intratumoral endothelial cells were isolated using magnetic beads coated with anti-CD31 antibodies. Cell lysates were then immunoblotted with antibodies recognizing phosphorylated Smad2/3, total Smad2/3 and actin.
avb8 integrin protein ( Figure 2) ; (3) oncogene-mediated transformation of astroglial progenitors results in a progressive reduction in avb8 integrin protein expression ( Figure 4) ; (4) stereotactic injection of transformed wild-type astroglial progenitors generates grade III anaplastic astrocytomas, whereas b8À/À cells give rise to tumors with vascular pathologies similar to grade IV GBM ( Figures 5 and 6) ; (5) the severe vascular pathologies in b8À/À tumors are largely ameliorated by exogenous expression of b8 integrin protein (Figure 7) and (6) b8À/À astrocytoma cells are impaired in their ability to activate latent TGFbs and stimulate TGFb signaling pathways in tumor-associated vascular endothelial cells (Figure 8) .
avb8 integrin-mediated interplay between TGFb and VEGF signaling pathways avb8 integrin is expressed in astrocytes and neural stem cells in the adult mouse brain, in which it negatively regulates angiogenesis (Mobley et al., 2009) . Interestingly, various reports have also shown that stem-like GBM cells, which are likely derived from neural stem cells and/or astrocytes, promote pathological angiogenesis to initiate and sustain tumor growth and progression (Bao et al., 2006b; Calabrese et al., 2007) . We propose that one mechanism used by GBM cells to circumvent the negative regulatory effects of avb8 integrin and promote tumor progression is to down-regulate integrin expression and function. Diminished integrin expression, combined with expression of pro-angiogenic factors, for example, VEGF, likely promotes neovessel formation necessary for tumor growth and progression. Interestingly, TGFbs have been reported to inhibit the pro-angiogenic and pro-permeability actions of VEGF (Ramsauer and D'Amore, 2007) . Here, we report a correlation between decreased integrin-mediated activation of TGFb signaling, and enhanced angiogenesis and vascular permeability ( Figures 5-8) , further supporting a model whereby integrin-activated TGFbs counteract the effects of VEGF (Supplementary Figure 5) . TGFb-mediated Smad3 phosphorylation in tumor cells has been reported to enhance VEGF gene expression (Petersen et al., 2010) . Interestingly, b8À/À astrocytoma cells, which have diminished TGFb activation capacities (Figure 8) , express reduced levels of VEGF mRNA and protein (Supplementary Figure 4 ). Collectively, these data suggest that integrin-mediated TGFb activation negatively regulates VEGF gene expression and VEGF-mediated signaling pathways during astrocytoma angiogenesis.
A potential role for avb8 integrin as a suppressor of astrocytoma progression The dramatic reduction in avb8 integrin protein expression that occurs following oncogene-mediated cell transformation also suggests that this integrin may have a suppressive role in tumor growth and/or progression. Although complete genetic ablation of b8 integrin expression does not lead to spontaneous brain tumorigenesis (Mobley et al., 2009) , it is possible that other genetic alterations, for example, activation of oncogenes or loss of a tumor suppressor functions may act in concert with diminished b8 integrin expression to promote spontaneous tumorigenesis. We have shown that genetic ablation of av integrin in epithelial cells of the skin leads to the development of squamous cell carcinoma over several post-natal months (McCarty et al., 2008) , further suggesting that genetic alterations acting in combination with loss of integrin expression contribute to tumorigenesis. Interestingly, in transformed astroglial cells b8 integrin protein expression is diminished at high passage numbers (Figure 4c ), which correlates with a timeline when astrocytes undergo spontaneous loss of the p53 locus (Bogler et al., 1995) . We are currently investigating functional links between avb8 integrin with oncogene and suppressor pathways in astrocytomas.
avb8 integrin and human gliomagenesis In another published report for b8 integrin in brain tumorigenesis, Louis and colleagues showed increased expression of b8 integrin mRNA in human GBM samples (Riemenschneider et al., 2005) . These analyses centered on integrin expression in primary GBMs, which arise de novo and harbor some genetic alterations that are distinct from secondary GBMs, which are more similar to the mosaic models that we have analyzed in this study. Hence, there may be distinct functions for avb8 integrin in primary versus secondary GBMs, possibly related to different genetic lesions contributing to tumor initiation and progression. In addition, the non-malignant samples analyzed by Louis and colleagues were from cerebral cortices, and not from the subventricular zone, which harbors neural stem and progenitor cells that likely give rise to GBMs (Zheng et al., 2008; Alcantara Llaguno et al., 2009) . Lastly, it is also possible that subpopulations of GBM cells, for example, those with stem-like properties that cluster around blood vessels (Bao et al., 2006b; Calabrese et al., 2007) , have diminished avb8 integrin expression/function. Any differences in integrin expression in this minority population of cells, however, would not be detected by analyzing bulk tumor masses. We are currently investigating the expression of avb8 integrin in low-and high-grade human astrocytomas to further determine the functions of this integrin in tumorinduced angiogenesis and other malignant processes.
Materials and methods
Experimental mice
Male NCR nu/nu mice were purchased from Jackson Laboratories and used for all experiments involving intracranial injections of mouse and human astrocytoma cells. b8 þ /À mice were obtained from the Mutant Mouse Regional Resource Center.
Antibodies, immunoblotting and immunofluorescence
The affinity-purified anti-av polyclonal antibody was generated by our laboratory using a synthetic peptide (ckrvrppqeeqereqlqphengegtsea) corresponding to a region of the chicken av cytoplasmic domain. The anti-b8 integrin antibody used for all immunoblotting has been described previously (McCarty et al., 2004 (McCarty et al., , 2005 . The following antibodies were purchased: rabbit anti-b1 integrin, rabbit anti-b5 integrin, rabbit antinestin and rat anti-mouse CD133 (Chemicon, Temecula, CA, USA), rat anti-mouse CD34 mAb (Genetex, Irvine, CA, USA), chicken anti-Nestin IgY (Neuromics, Edina, MN, USA), rat anti-mouse CD31 and rat anti-mouse av-PE mAbs (BD Biosciences, San Jose, CA, USA), rabbit anti-b-actin pAb (Sigma, St Louis, MO, USA), rabbit anti-GFAP pAb (Dako, Carpinteria, CA, USA), rabbit anti-pSmad3 mAb (Epitomics, Burlingame, CA, USA) and anti-Ras and anti-E7 antibodies (Santa Cruz Biotech, Santa Cruz, CA, USA). Mouse anti-VEGF, rabbit anti-Desmin as well as rabbit anti-pSmad2 and tSmad2/3 antibodies were purchased from Cell Signaling Technologies (Beverly, MA, USA). The anti-V5 mAb was purchased form Clontech Laboratories (Mountanview, CA, USA). Secondary antibodies were goat anti-rabbit, goat antichicken, goat anti-rat and goat anti-mouse, all conjugated to Alexa Fluor 488 or Alexa Fluor 594 (Molecular Probes, Carlsbad, CA, USA). For quantitation of blood vessel densities, we captured digital images from sections stained for CD34 immunofluorescence. Mean fluorescence intensity was calculated using ImageJ software (NIH, Bethesda, MD, USA). Two investigators, who were masked to the genotypes for each sample, analyzed fluorescent sections.
Isolation and propagation of murine astroglial progenitors and human astrocytoma cell lines Astroglial progenitors were cultured from cerebral cortices of wild-type or b8À/À neonates (P0) and propagated on laminin-coated dishes, as described previously (McCarty et al., 2005) . To generate retroviral stocks, we transfected 293T Phoenix cells with pLXSP-puro-E6/E7 and pLXSNneo-G12V H-Ras (Sonoda et al., 2001b) . Primary astroglial cells were transduced with the E6/E7 retroviral supernatant and cells were selected in growth media containing 1 mg/ml puromycin for 5 days. Puromycin-resistant clones were pooled and transduced with G12V H-Ras retrovirus supernatant, and selected after 10 days in G418 (900 mg/ml). To analyze integrin expression in passaged cells, we trypsinized semi-confluent monolayers of cells and split 1:5 onto new dishes. After reaching 80-90% confluence the procedure was repeated. Transformed b8À/À cells were transfected with empty vector (pcDNA4-V5) or vector containing the full-length human b8 integrin cDNA (pcDNA4-b8V5) (McCarty et al., 2004 (McCarty et al., , 2005 . Stable transfectants were selected by growth in Zeocin (300 mg/ ml) for 10 days, and integrin overexpression was confirmed by immunoblotting lysates with anti-b8 or anti-V5 antibodies. U87 and LN229 astrocytoma cells were purchased from American Tissue Culture Collection (ATCC) and were propagated in Dulbecco's modified Eagle's medium/F12 supplemented with 10% bovine serum and antibiotics. U251 and SNB19 cells were kindly provided by Dr Oliver Bogler and Dr Dimpy Koul (both at MDACC), respectively, and were grown in Dulbecco's modified Eagle's medium/F12 supplemented with 10% bovine serum and antibiotics.
Soft Agar growth assays A 1% solution of sterile DNA-grade agarose was mixed with 2 Â Dulbecco's modified Eagle's medium, and the 1 Â base solution was added to six-well dishes and was solidified. The transformed astrocytes (20 000 cells per ml in 2 Â media) were mixed with a 0.7% agarose solution, and 5000 cells were added to the base agarose. The plates were incubated at 37 1C for 1-2 weeks. Cells were fixed with 4% paraformaldehyde/phosphatebuffered saline and stained with 0.1% crystal violet.
Intracranial injections of transformed astroglial cells and human astrocytoma cells
Nude mice were anesthetized and a single incision was made from the anterior pole of the skull to the posterior ridge. A hole was drilled over the target brain structure to expose the brain. We targeted the striatum for cell implantation using the following stereotactic coordinates, all relative to the bregma: 1.5 mm rostral, 1.5 mm anterior and 4 mm below the pial surface. An automated micropump (Stoelting Instruments, Wood Dale, IL, USA) was used to dispense cells in 3-5 ml phosphate-buffered saline over a 5-min period. Astroglial progenitors cultured for less than four passages after transformation were used for the experiments. In the Kaplan-Meier survival study 2.5 Â 10 4 transformed cells were injected, and animals were monitored until development of tumor-induced neurological phenotypes. In other experiments, nude mice were stereotactically injected with 1 Â 10 5 wild-type or b8À/À transformed cells and tumorbearing animals were perfused with 4% paraformaldehyde/ phosphate-buffered saline. Brains were coronally sliced at 1 mm intervals and paraffin-embedded tissue was serially sectioned at 7 mm intervals. Human intracranial xenograft tumors were generated by injecting 5 Â 10 5 U87 or SNB19 cells into immunocompromised mice.
Isolation of CD31 þ intratumoral cells
Mice harboring 21-day-old intracranial tumors derived from b8À/À ( þ vector) or b8À/À ( þ b8V5) transformed astroglial progenitors were killed. Tumors were then microdissected from the brain and dissociated into a single-cell suspension using neural tissue dissociation media (Rietze and Reynolds, 2006) . CD31-expressing cells were sorted using a rat antimouse CD31 antibody (BD Biosciences), magnetic beads coated with goat anti-rat secondary antibody (Miltenyi Biotec Inc, Auburn, CA, USA), and a BioMag magnetic separation unit (Polysciences Inc, Warrington, PA, USA).
Luciferase reporter assays
Mink lung epithelial cells stably transfected with a PAI-1luciferase plasmid (Abe et al., 1994) were seeded onto polylysine-coated six-well plates at 4 Â 10 5 cells per well. After 12 h media were removed and serum-free media were added for 24 h. Conditioned media from wild-type and b8À/À transformed astroglial progenitor cells preincubated for 12 h with or without 10 ng/ml LAP-TGFb1 (R&D Systems, Minneapolis, MN, USA) were collected and added to MLECs for 12 h. Cell lysates were then prepared and luciferase substrates were added and quantified using an Enhanced Luciferase Assay Kit (BD Biosciences).
Statistical analyses
Student's t-test was used to determine statistically significant differences. The Wilcoxon rank-sum test was used for analysis of Kaplan-Meier survival results.
